Robert Kwun, MD
Retina Specialist · Salt Lake City, UTNPI 1457338162
Payments from drug & device makers
Across 801 payments — averaging $2465.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.1M
- Boehringer Ingelheim$177K
- Regeneron Healthcare Solutions, Inc.$167K
- Boehringer Ingelheim International GmbH$125K
- Janssen Research & Development, LLC$116K
- Genentech USA, Inc.$102K
- plus $185K from 15 others
What the payments were for
- Consulting fees$35,48111%
- Speaking & faculty fees$236,54271%
- Travel & lodging$50,20715%
- Food & beverage$9,9843%
- Ownership interest$2,1851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 91 | $1,102,019 |
| Boehringer Ingelheim | 16 | $177,111 |
| Regeneron Healthcare Solutions, Inc. | 156 | $167,421 |
| Boehringer Ingelheim International GmbH | 139 | $125,278 |
| Janssen Research & Development, LLC | 20 | $115,947 |
| Genentech USA, Inc. | 117 | $102,043 |
| Regeneron | 129 | $86,146 |
| Novartis | 37 | $36,866 |
| Astellas Pharma Global Development | 14 | $36,531 |
| AbbVie(2 entities) | 34 | $12,343 |
| Hexal AG | 1 | $5,000 |
| Alimera Sciences, Inc. | 8 | $2,675 |
| US Retina LLC | 10 | $2,185 |
| Apellis Pharmaceuticals, Inc. | 4 | $934 |
| BD | 1 | $900 |
| Eyepoint US, Inc. | 13 | $594 |
| Astellas Pharma US Inc | 6 | $248 |
| Cardinal Health 110 LLC | 1 | $150 |
| Biogen | 2 | $88 |
| Amgen | 1 | $74 |
| Glaukos Corporation | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,974,605 in reported general payments places this provider in the 90th percentile of 20 retina specialist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 25 | $908 |
| Bromfenac Sodium | 12 | $617 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $388 |
| Timolol Maleate | 26 | $355 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Salt Lake City
- James HowardSalt Lake City$2.8M
- Mitchell GoffSalt Lake City$1.7M
- David FaberSalt Lake City$412K
- Rebekah GensureSalt Lake City$5K
- Kirk WinwardSalt Lake City$3K
- Eric BrintonSalt Lake City$3K
- Gregory BrintonSalt Lake City$1K
- Mano SwartzSalt Lake City$28
- Douglas MehrWest Jordan$34K
- Andrew DavisWest Jordan$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.